CARNA BIOSCIENCES

News Release

May 13, 2026
Carna Biosciences, Inc.

Carna to Present Updated Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2026

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that updated results from an ongoing Phase 1b study of docirbrutinib (AS-1763) will be presented at the European Hematology Association (EHA) 2026 Congress, to be held in Stockholm, Sweden June 11-14.

Docirbrutinib is an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner. It is currently under development for the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies who have developed resistance or are intolerant to at least two prior lines of systemic therapy including a covalent BTK inhibitor (NCT05602363).

The poster will be presented by Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center with all principal investigators from the participating clinical sites serving as co-authors.

Presentation Details

Abstract Code: PS1690

Poster title:	Updated Results from a Phase 1b Study of Non-covalent Pan-mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-cell Malignancies
Session:	Poster session
Session date:	June 13, 2026
Presenter:	Nitin Jain[1], Catherine Coombs[2], Nirav N. Shah[3], Jonathan S. Goldberg[4] , Seung Tae Lee[5], Jacqueline Barrientos[6], Sunil Babu[7], John Nemunaitis[8], Shuo Ma[9], Andrew Gills-Smith[10], Danielle M. Brander[11], Julio Peguero[12], Shirou Kirita[13], Koji Yoshida[13], Masaaki Sawa[13], Kyoko Miyamoto[14], Akinori Arimura[14], William Wierda[1], Varsha Gandhi[15], Javier Pinilla[16]

[1]The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, [2]University of California Irvine, Division of Hematology/Oncology, [3]Medical College of Wisconsin, Division of Hematology/Oncology, [4]Optum Medical Care, Department of Hematology and Oncology, [5]University of Maryland, Greenebaum Comprehensive Cancer, [6]Mount Sinai Medical Center, [7]American Oncology Partners, Fort Wayne Medical Oncology and Hematology, [8]Taylor Cancer Research Center, [9]Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Division of

Hematology-Oncology, [10]University of Massachusetts Memorial Medical Center, Hematology/Oncology, [11]Duke Cancer Institute, Division of Hematologic Malignancies and Cellular Therapy, [12]Oncology Consultants, [13]Carna Biosciences, Inc., [14]CarnaBio USA, Inc., [15]The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, [16]Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute

The abstract is now available at:

URL: https://library.ehaweb.org/eha/2026/eha-2026/4208242/

About docirbrutinib (AS-1763)

Docirbrutinib is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S - 2 -mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitor, recently approved pirtobrutinib, has been reported. Docirbrutinib potently inhibited both wild type and those mutant BTKs, strongly suggesting that docirbrutinib will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of docirbrutinib as a next-generation BTK inhibitor. The Phase 1b study of docirbrutinib is being conducted in the U.S. and dosing in the dose expansion part is ongoing (NCT05602363).

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/